RSS-Feed abonnieren
DOI: 10.1055/s-2001-14502
Hepatische Enzephalopathie
Hepatic encephalopathyPublikationsverlauf
Publikationsdatum:
11. September 2002 (online)

Die hepatische Enzephalopathie (HE) ist eine metabolisch induzierte, potenziell reversible Funktionsstörung des Zentralnervensystems im Rahmen von Leberkrankheiten. Im weitesten Sinne schließt sie alle neuropsychiatrischen Syndrome, die bei akuten oder chronischen Lebererkrankungen auftreten können und kausal durch die Leberfunktionsstörung bedingt sind, ein. Die HE umfasst ein breites Spektrum unterschiedlicher klinischer Zustandsbilder. Zahlreiche Synonyme geben meist nur Teilaspekte wieder. Voraussetzung für die Diagnose einer HE ist der Nachweis einer Lebererkrankung, der Nachweis einer Funktionsstörung des zentralen Nervensystems und der sichere Ausschluss einer anderen neurologischen Erkrankung. Während der Nachweis einer Lebererkrankung bzw. die Diagnose der Funktionsstörung des zentralen Nervensystems unproblematisch ist, kann die Abgrenzung zu anderen neurologischen Erkrankungen, die bei Leberkrankheiten auftreten können, schwierig sein.
Literatur
- 1
Amodio P, Marchetti P, Del Piccolo F. et al .
Visual attention in cirrhotic patients.
Hepatology.
1998;
27
1517-1523
MissingFormLabel
- 2
Amodio P, Marchetti P, Del P iccolo F, de Tourtchaninoff M, Varghese P, Zuliani C. et al .
Spectral versus visual EEG analysis in
mild hepatic encephalopathy.
Clin Neurophysiol.
1999;
110
1334-1344
MissingFormLabel
- 3
Baraldi M, Zeneroli M L.
Experimental
hepatic encephalopathy - changes in gamma-amino-butyric
acid.
Science.
1982;
216
427-431
MissingFormLabel
- 4
Barbaro G, Di
Lorenzo G, Soldini M. et
al .
Flumazenil for hepatic encephalopathy grade III
and IVa in patients with cirrhosis.
Hepatology.
1998;
28
374-378
MissingFormLabel
- 5
Basile A S, Pandl L, Jaouni T. et al .
Brain concentrations of benzodiazepines
are elevated in an animal model of hepatic encephalopathy.
Proc Natl
Acad Sci USA.
1990;
87
5263-5267
MissingFormLabel
- 6
Basile A S, Harrison P M, Hughes R D. et al. .
Relationship between plasma benzodiazepine
receptor ligand concentrations and severity of hepatic encephalopathy.
Hepatology.
1994;
19
112-121
MissingFormLabel
- 7
Bucci L, Palmieri G C.
Double-blind,
double-dummy comparison between treatment with rifaximin and lactulose
in patients with medium to severe degree hepatic encephalopathy.
Curr-Med
Res Opin.
1993;
13
109-118
MissingFormLabel
- 8
Butterworth R F.
The
astrocytic (»peripheral-type«) benzodiazepine
receptor.
Neurochem Int.
2000;
36
411-416
MissingFormLabel
- 9
Cadranel J F, el Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D, Opolon P.
Flumazenil
therapy for hepatic encephalopathy in cirrhotic patients.
Eur
J Gastroenterol Hepatol.
1995;
7
325-329
MissingFormLabel
- 10
Chan H, Hazell A S, Desjardins P, Butterworth R F.
Effects
of ammonia on glutamate transporter (GLAST) protein and mRNA in
cultured rat cortical astrocytes.
Neurochem Int.
2000;
37
243-248
MissingFormLabel
- 11
Conn H O, Leevy C M, Vlahcevic Z R, Rodgers J B, Maddrey W C, Seeff L, Levy L L.
Comparison
of Lactulose and Neomycin in the Treatment of Chronic Portal-systemic
Encephalopathy.
Gastroenterology.
1977;
72
573-583
MissingFormLabel
- 12
Desjardins P, Rao K V, Michalak A, Rose C, Butterworth R F.
Effect
of portacaval anastomosis on glutamine synthetase protein and gene
expression in brain, liver and skeletal muscle.
Metab
Brain Dis.
1999;
14
273-280
MissingFormLabel
- 13
Egberts E H, Schomerus H, Hamster W, Jürgens P.
Branched Chain
Amino Acids in the Treatment of Latent Portosystemic Encephalopathy.
Gastroenterology.
1985;
88
887-895
MissingFormLabel
- 14
Efrati C, Masini A, Merli M, Valeriano V, Riggio O.
Effect of sodium benzoate on
blood ammonia response to oral glutamine challenge in cirrhotic
patients: a note of caution.
Am J Gastroenterol.
2000;
95
3574-3578
MissingFormLabel
- 15 Ferenci P. Diagnosis
and differential diagnosis of hepatic encephalopathy: Implications
for the design of clinical studies. Univ. of Newcastle upon
Tyne In: Advances in Hepatic encephalopathy and
metabolism in liver diseases. CO Record, H Al Mardini (eds) 1997: 267-272
MissingFormLabel
- 16
Ferenci P.
Hepatische
Enzephalopathie: Ernährung als Ursache oder Therapie?.
Z
f Gastroenterologie.
1996;
34
32-34
(Suppl 5)
MissingFormLabel
- 17
Fischer J E, Baldessarini R J.
False
neurotransmitters and hepatic failure.
ancet.
1971;
ii
75-80
MissingFormLabel
- 18
Grippon P, Le Poncin-Laffite M, Boschat M. et al .
Evidence for the role of ammonia in the
intracerebral transfer and metabolism of tryptophan.
Hepatology.
1986;
6
682-6686
MissingFormLabel
- 19
Groeneweg M, Gyr K, Amrein R, Scollo-Lavizzari G, Williams R, Yoo J Y, Schalm S W.
Effect of flumazenil
on the electroencephalogram of patients with portosystemic encephalopathy.
Results of a double blind, randomized, placebo-controlled multicenter
trial.
Electroencephalogr Clin Neurophysiol.
1996;
98
29-34
MissingFormLabel
- 20
Horst D, Grace N D, Conn H O. et al .
Comparison
of dietary protein with an oral, branched chain-enriched amino acid
supplement in chronic portal-systemic encephalopathy.
Hepatology.
1984;
4
279-287
MissingFormLabel
- 21
Hartmann I J, Groeneweg M, Quero J C, Beijeman S J, de Man R A, Hop W C, Schalm S W.
The
prognostic significance of subclinical hepatic encephalopathy.
Am
J Gastroenterol.
2000;
95
2029-2034
MissingFormLabel
- 22
Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S.
Hepatic
encephalopathy in chronic liver disease: A clinical manifestation
of astrocyte swelling and low-grade cerebral edema?.
J
Hepatol.
2000;
32
1035-1038
MissingFormLabel
- 23
Kircheis G, Nilius R, Held C. et
al .
Therapeutic efficacy of L-ornithine-L-aspartate
infusions in patients with cirrhosis and hepatic encephalopathy:
results of a placebo-controlled, double blind study.
Hepatology.
1997;
25
1351-1360
MissingFormLabel
- 24
Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, Madl C.
Comparison
of ammonia partial pressure and total ammonia in hepatic encephalopathy.
Hepatology.
2000;
31
30-34
MissingFormLabel
- 25
Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H.
Manganese and chronic
hepatic encephalopathy.
Lancet.
1995;
346
270-274
MissingFormLabel
- 26
Kullmann F, Hollerbach S, Holstege A, Schölmerich J.
Subclinical
hepatic encephalopathy.
J Hepatol.
1995;
22
101-110
MissingFormLabel
- 27
Loguercio C, Abbiati R, Rinaldi M, Romano A, del Vecchio
Blanco C, Coltori M.
Long-term
effects of enterococcus faecium SF68 versus lactulose in the treatment
of patients with cirrhosis and grade 1 - 2
hepatic encephalopathy.
J Hepatology.
1995;
23
39-46
MissingFormLabel
- 28
Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M.
Zinc
supplementation and amino acid-nitrogen metabolism in patients with
advanced cirrhosis.
Hepatology.
1996;
23
1084-1092
MissingFormLabel
- 29
Mendenhall C L, Rouster S, Marshall L, Weesner R.
A New Therapy for Portal Systemic
Encephalopathy.
Amer J Gastroenterol.
1986;
81
540-543
MissingFormLabel
- 30
Michalak A, Chatauret N, Butterworth R F.
Evidence
for a serotonin transporter deficit in experimental acute liver
failure.
Neurochem Int.
2001;
38
163-168
MissingFormLabel
- 31
Michalak A, Rose C, Butterworth J, Butterworth R F.
Neuroactive
amino acids and glutamate (NMDA) receptors in frontal cortex of
rats with experimental acute liver failure.
Hepatology.
1996;
24
908-913
MissingFormLabel
- 32
Morgan M Y, Hawley K E.
Lactitol vs.
lactulose in the treatment of acute hepatic encephalopathy in cirrhotic
patients: A double blind, randomized trial.
Hepatology.
1987;
7
1278-1284
MissingFormLabel
- 33
Naylor C D, O’Rourkee K, Detsky A S, Baker J P.
Parenteral nutrition
with branched-chain amino acids in hepatic encephalopathy. A Meta-Analysis.
Gastroenterology.
1989;
97
1033-1042
MissingFormLabel
- 34 Orlandi F, Brunelli E, Benedetti A, Macarri G. Clinical trials of nonabsorbable
disaccharide therapy in hepatic encephalopathy. Medi-Ed
Press, Bloomington in: Hepatic encephalopathy.
Syndromes and Therapies. Conn HO and Bircher J. (eds) 1994: 209-218
MissingFormLabel
- 35
Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Müller M J.
ESPEN Guidelines
for nutrition in liver disease and transplantation.
Clin
Nutrition.
1997;
16
43-55
MissingFormLabel
- 36
Pomier-Layrargues J F, Giguère J, Lavoie J. et al .
Flumazenil in cirrhotic patients in hepatic
coma:A randomized double-blind placebo-controlled crossover trial.
Hepatology.
1994;
19
32-37
MissingFormLabel
- 37
Quero J C, Hartmann J C, Meulstee J, Hop W C, Schalm S W.
The
diagnosis of subclinical encephalopathy in patients with cirrhosis
using neuropsychological tests and automated electroencephalogram
analysis.
Hepatology.
1996;
24
556-560
MissingFormLabel
- 38 Raabe W. Neuronal
effects of ammonia. Elsevier, Amsterdam In:
Advances in ammonia metabolism and hepatic encephalopathy. Soeters
P, Wilson JHP, Meijer AF, Holm E (eds) 1988: 349-355
MissingFormLabel
- 39
Rees C J, Oppong K, Al Mardini H, Hudson M, Record C O.
Effect
of L-ornithine-L-aspartate on patients with and without TIPS undergoing
glutamine challenge: a double blind, placebo controlled trial.
Gut.
2000;
47
571-574
MissingFormLabel
- 40
Reding P, Duchateau J, Bataille C.
Oral zinc supplementation
improves hepatic encephalopathy.
Lancet.
1984;
ii
493-495
MissingFormLabel
- 41
Riggio O, Ariosto F. et al .
Short-term oral zinc supplementation does
not improve chronic hepatic encephalopathy.
Dig Dis Sci.
1991;
36
1204-1208
MissingFormLabel
- 42
Ross B D, Jacobson S, Villamil F, Korula J, Kreis R, Ernst T. et al .
Subclinical hepatic encephalopathy.
Radiology.
1994;
193
457-463
MissingFormLabel
- 43
Rudman D, Smith R B, Salam A A. et al .
The
amino acid content of food.
Am J Clin Nutr.
1973;
26
487-490
MissingFormLabel
- 44
Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E.
Effects of
ornithine aspartate on plasma ammonia and plasma amino acids in patients
with cirrhosis.
J Hepatol.
1993;
19
424-430
MissingFormLabel
- 45
Strauss E, Tramote R, Silva E P, Caly W R, Honain N Z, Maffei R A, de Sa M F.
Double-blind
randomized clinical trial comparing neomycin and placebo in the
treatment of exogenous hepatic encephalopathy.
Hepatogastroenterology.
1992;
39
542-545
MissingFormLabel
- 46
Sushma S, Dasarathy S, Tandon R K, Jain S, Gupta S, Bhist M S.
Sodium benzoate
in the treatment of acute hepatic encephalopathy: a double-blind
randomized trial.
Hepatology.
1992;
16
138-144
MissingFormLabel
- 47
Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T. et
al .
Successful use of vancomycin hydrochloride in the
treatment of lactulose resistant chronic hepatic encephalopathy.
Gut.
1990;
31
702-706
MissingFormLabel
- 48
Tromm A, Griga T, Greving I, Hilden H, Huppe D, Schwegler U. et al .
Orthograde whole gut irrigation with mannite
versus paromomycine + lactulose as prophylaxis of hepatic
encephalopathy in patients with cirrhosis and upper gastrointestinal
bleeding: Results of a controlled randomized trial.
Hepatogastroenterology.
2000;
47
473-477
MissingFormLabel
- 49
Uribe M, Campollo O, Vargas F.
Acidifying enemas (lactitol
and lactulose) vs. nonacidifying enemas (tap water) to treat acute
portal-systemic encephalopathy: A double-blind randomized clinical
trial.
Hepatology.
1987;
7
639-634
MissingFormLabel
- 50
Uribe M, Marquez M A, Gargaramos G. et al .
Treatment
of chronic portal systemic encephalopathy with lactose in lactase
deficient patients.
Dig Dis Sci.
1980;
25
914-928
MissingFormLabel
- 51
Van der Rijt C C, Schalm S W, Meulstee J, Stijnen T.
Flumazenil therapy for
hepatic encephalopathy. A double-blind cross over study.
Gastroenterol
Clin Biol.
1995;
19
572-580
MissingFormLabel
- 52
Van der Rijt C C, Schalm S W, Schat H, Foeken K, De Jong G.
Overt
hepatic encephalopathy precipitated by zinc deficiency.
Gastroenterology.
1991;
100
1114-1118
MissingFormLabel
- 53
Vogels B APM, Maas M AW, Daalhuisen J, Quack G, Chamuleau R AFM.
Memantine,
a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced
encephalopathy and acute hepatic encephalopathy in rats.
Hepatology.
1997;
25
820-827
MissingFormLabel
- 54
Weber F L, Minco D, Fresard K M, Banwell J G.
Effects of
vegetable diets on nitrogen metabolism in cirrhotic subjects.
Gastroenterology.
1985;
89
538-544
MissingFormLabel
- 55
Weissenborn K, Rückert N, Hecker H, Manns M P.
The number connection
tests A and B: Interindividual variability and use for the assessment
of early hepatic encephalopathy.
J Hepatol.
1998;
28
646-653
MissingFormLabel
- 56
Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla H R. et al .
Elevated serum levels of astroglial S100beta
in patients with liver cirrhosis indicate early and subclinical
portal-systemic encephalopathy.
Metab Brain Dis.
1999;
14
239-251
MissingFormLabel
- 57
Yurdaydin C, Herneth A, Steindl P, Singer E, Ferenci P.
Modulation
of hepatic encephalopathy in rats with thioacetamide-induced acute
liver failure by serotonin antagonists.
Eur J Gastroenterol
Hepatol.
1996;
8
664-671
MissingFormLabel
- 58
Yurdaydin C, Hörtnagl H, Steindl P, Zimmermann C, Pifl C, Singer E A, Roth E, Ferenci P.
Increased serotoninergic
and noradrenergic activity in hepatic encephalopathy in rats with
thioacetamide induced acute liver failure.
Hepatology.
1990;
12
695-700
MissingFormLabel
Univ. Prof. Dr. Peter Ferenci
Universitätsklinik für Innere Medizin
IV Klinische Abteilung Gastroenterologie und Hepatologie
Währinger Gürtel 18-20
A-1090 Wien
eMail: peter.ferenci@akh-wien.ac.at